CN110448554B - D-青霉胺联合氟康唑在制备抗真菌产品中的应用 - Google Patents
D-青霉胺联合氟康唑在制备抗真菌产品中的应用 Download PDFInfo
- Publication number
- CN110448554B CN110448554B CN201910865983.8A CN201910865983A CN110448554B CN 110448554 B CN110448554 B CN 110448554B CN 201910865983 A CN201910865983 A CN 201910865983A CN 110448554 B CN110448554 B CN 110448554B
- Authority
- CN
- China
- Prior art keywords
- penicillamine
- fluconazole
- candida
- diseases
- antifungal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004884 fluconazole Drugs 0.000 title claims abstract description 66
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 title claims abstract description 66
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 title claims abstract description 58
- 229960001639 penicillamine Drugs 0.000 title claims abstract description 56
- 230000000843 anti-fungal effect Effects 0.000 title claims abstract description 26
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 73
- 229940079593 drug Drugs 0.000 claims abstract description 52
- 241000222122 Candida albicans Species 0.000 claims abstract description 38
- 229940095731 candida albicans Drugs 0.000 claims abstract description 37
- 241000233866 Fungi Species 0.000 claims abstract description 11
- 239000003429 antifungal agent Substances 0.000 claims abstract description 6
- 230000005764 inhibitory process Effects 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 150000003852 triazoles Chemical class 0.000 claims description 9
- 206010007134 Candida infections Diseases 0.000 claims description 5
- 201000003984 candidiasis Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000009278 visceral effect Effects 0.000 claims description 4
- 210000004013 groin Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000007027 Oral Candidiasis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 241000287411 Turdidae Species 0.000 claims description 2
- 206010046914 Vaginal infection Diseases 0.000 claims description 2
- 201000008100 Vaginitis Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 201000003465 angular cheilitis Diseases 0.000 claims description 2
- 210000000436 anus Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 208000007287 cheilitis Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010034016 Paronychia Diseases 0.000 claims 1
- 241000029132 Paronychia Species 0.000 claims 1
- 206010054152 Skin candida Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 208000037911 visceral disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 238000011160 research Methods 0.000 abstract description 13
- 206010059866 Drug resistance Diseases 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 229940000425 combination drug Drugs 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 21
- 239000012980 RPMI-1640 medium Substances 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102100032566 Carbonic anhydrase-related protein 10 Human genes 0.000 description 5
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 5
- 101000867836 Homo sapiens Carbonic anhydrase-related protein 10 Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 3
- 208000018839 Wilson disease Diseases 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 241000579895 Chlorostilbon Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 206010027439 Metal poisoning Diseases 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229910052876 emerald Inorganic materials 0.000 description 2
- 239000010976 emerald Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000013048 microbiological method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000029011 Copper metabolism disease Diseases 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000005035 cutaneous candidiasis Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 206010052366 systemic mycosis Diseases 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910865983.8A CN110448554B (zh) | 2019-09-12 | 2019-09-12 | D-青霉胺联合氟康唑在制备抗真菌产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910865983.8A CN110448554B (zh) | 2019-09-12 | 2019-09-12 | D-青霉胺联合氟康唑在制备抗真菌产品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110448554A CN110448554A (zh) | 2019-11-15 |
CN110448554B true CN110448554B (zh) | 2022-06-07 |
Family
ID=68491900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910865983.8A Active CN110448554B (zh) | 2019-09-12 | 2019-09-12 | D-青霉胺联合氟康唑在制备抗真菌产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110448554B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111700885B (zh) * | 2020-08-06 | 2021-06-04 | 山东省千佛山医院 | 苄丝肼、及与氟康唑的组合物在制备抗真菌产品中的应用 |
CN115414487B (zh) * | 2022-09-07 | 2023-09-22 | 山东省妇幼保健院 | 千金藤素联合大环内酯类抗生素在制备抗菌产品中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267979B1 (en) * | 1997-08-26 | 2001-07-31 | Wake Forest University | Chelators in combination with biocides: treatment of microbially induced biofilm and corrosion |
CN102056600A (zh) * | 2008-04-07 | 2011-05-11 | 界面生物公司 | 用于治疗细菌感染的组合疗法 |
WO2017180714A1 (en) * | 2016-04-12 | 2017-10-19 | University Of Kansas | ANTIFUNGAL ACTIVITY OF lRON SEQUESTERING POLYMERS |
CN108522518A (zh) * | 2017-09-26 | 2018-09-14 | 华南农业大学 | 一种三唑农药-铜络合物杀菌剂的制备与应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040208842A1 (en) * | 2001-09-18 | 2004-10-21 | Ritchie Branson W. | Antimicrobial cleansing compositions and methods of use |
-
2019
- 2019-09-12 CN CN201910865983.8A patent/CN110448554B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267979B1 (en) * | 1997-08-26 | 2001-07-31 | Wake Forest University | Chelators in combination with biocides: treatment of microbially induced biofilm and corrosion |
CN102056600A (zh) * | 2008-04-07 | 2011-05-11 | 界面生物公司 | 用于治疗细菌感染的组合疗法 |
WO2017180714A1 (en) * | 2016-04-12 | 2017-10-19 | University Of Kansas | ANTIFUNGAL ACTIVITY OF lRON SEQUESTERING POLYMERS |
CN108522518A (zh) * | 2017-09-26 | 2018-09-14 | 华南农业大学 | 一种三唑农药-铜络合物杀菌剂的制备与应用 |
Non-Patent Citations (3)
Title |
---|
Determination of human teratogenicity by the astute clinician method: Review of illustrative agents and a proposal of guidelines;John C. Carey等;《Birth Defects Res A Clin Mol Teratol》;20091231;第85卷(第1期);63-68 * |
Potent Synergistic Effect of Doxycycline with Fluconazole against Candida albicans Is Mediated by Interference with Iron Homeostasis;Alessandro Fiori等;《Antimicrob Agents Chemother》;20121231;第56卷(第7期);3785-3796 * |
Synergistic antifungal effect of lactoferrin with azole antifungals against Candida albicans and a proposal for a new treatment method for invasive candidiasis;Tsutomu Kobayashi等;《Jpn J Infect Dis》;20111231;第64卷(第4期);292-296 * |
Also Published As
Publication number | Publication date |
---|---|
CN110448554A (zh) | 2019-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110448554B (zh) | D-青霉胺联合氟康唑在制备抗真菌产品中的应用 | |
CN113384570B (zh) | 咖啡酸甲酯及与三唑类组合物在制备抗真菌产品中的应用 | |
CN107519167B (zh) | 盐酸去氢骆驼蓬碱联合氟康唑的抗白色念珠菌产品及其应用 | |
CN108478566B (zh) | 丁苯酞在制备抗真菌产品中的应用及其产品 | |
CN111700885A (zh) | 苄丝肼、及与氟康唑的组合物在制备抗真菌产品中的应用 | |
CN115192593B (zh) | 柔红霉素在治疗多重耐药菌感染疾病中的应用 | |
CN105663126B (zh) | 盐酸氨溴索联合氟康唑的抗真菌产品及其应用 | |
WO2017038872A1 (ja) | 抗真菌活性を有する組成物 | |
CN107412227B (zh) | 一种蒽醌类化合物在制备抗真菌药物中的应用及抗真菌组合物 | |
Belal et al. | Nitrogen-doped carbon quantum dots as a novel treatment for black fungal bone infections (Mucormycosis): in vitro and in vivo study | |
CN107875154B (zh) | 含有哌拉西林的组合物、其药物制剂及其应用 | |
CN107050421A (zh) | N15多肽在制备真菌抑制剂中的用途 | |
CN103099828B (zh) | 维生素c泡腾片 | |
CN107898789B (zh) | 白屈菜红碱联合氟康唑在制备抗真菌产品中的应用及其产品 | |
WO2010082182A1 (en) | Fulvic acid in combination with fluconazole or amphotericin b for the treatment of fungal infections | |
CN114159474B (zh) | 六神丸在制备治疗真菌性肺炎的药物中的应用 | |
CN101011409B (zh) | 一种维生素b12滴鼻液组合物 | |
CN113101284B (zh) | 大蒜辣素在制备抗酵母菌药物中的应用 | |
CN114209835B (zh) | 一种念珠菌属感染疾病的治疗药物 | |
CN114288307B (zh) | 一种含唾液酸盐的产品及其应用 | |
CN114042100B (zh) | 含中药提取物的抗菌组合物及其应用 | |
CN115919883B (zh) | 一种具有抗球形马拉色菌耐药性作用的组合物及其制备方法 | |
CN104083360B (zh) | 一种用于制备抗曲霉菌药物的中药组合物 | |
CN102648904B (zh) | 姜黄素-锌化合物在制备保健护理品中的应用 | |
CN112759627B (zh) | 一种抗白色念珠菌多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Xiuyun Inventor after: Li Yiman Inventor after: Hao Lina Inventor after: Gao Yan Inventor after: Tan Yufeng Inventor after: Liu Yalu Inventor before: Hao Lina Inventor before: Li Yiman Inventor before: Li Xiuyun Inventor before: Gao Yan Inventor before: Tan Yufeng Inventor before: Liu Yalu |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210129 Address after: No.238, Jingshi East Road, Lixia District, Jinan City, Shandong Province, 250102 Applicant after: SHANDONG MATERNAL AND CHILD HEALTH Hospital Address before: 250022 No. 23976, No. ten road, Huaiyin District, Ji'nan, Shandong Applicant before: JINAN CHILDREN'S HOSPITAL (QILU CHILDREN'S HOSPITAL OF SHANDONG University) |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |